<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221121056570N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-29</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of adding traditional medicine treatments (honey and frankincense extract) to common treatments on polyuria in patients with diabetes insipidus</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of adding traditional medicine treatments (honey and frankincense extract) to common treatments on hyperuria in patients with diabetes insipidus in the intensive care unit -a preliminary study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67310</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment to intervention and control groups is done individually.
All patients who have polyuria caused by diabetes insipidus in the intensive care unit will be included in the study after obtaining written informed  consent if they meet the inclusion criteria and do not have the exclusion criteria. The patient is entered into one of the intervention 1, intervention 2 or control groups according to the order of entering the department, based on the blocks (n=6) of random numbers that were previously prepared by the statistical consultant with the software.
The statistician who made the random blocks did not know how to assign treatment groups (control, intervention 1 or intervention 2), Blinding description: In this study, the participants (patient and his family), nurses, principal investigator, data collectors and outcome assessors are unaware of study group allocation.
Allocating the control or intervention group to the cases and drawing the drug in the syringe is done by a person who is not among the researchers or nurses taking care of the patient.</study_design>
      <phase>2</phase>
      <hc_freetext>neurogenic diabetes insipidus due to brain diseases or head injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: a group of patients who, receive traditional medicine including honey and frankincense extract as gavage every 12 hours for 48 hours in addition to classical treatments for diabetes insipidus,  (10 ml of honey and 500 mg of frankincense extract dissolved in 20 ml of distilled water). Conventional treatments for diabetes insipidus include replacing the deficit of fluids with intravenous or oral solutions with minimal sodium (half saline, dextrose 5% or water) with a daily volume of approximately 4 ml per kilogram of body weight and reducing the volume of urine through the administration of Desmopressin (synthetic analogue of vasopressin) nasal spray 1-2 puff (10-40 microgram) every 12 hours and the treatment of primary brain disease. Intervention 2: Intervention group 2 : a group of patients who, receive traditional medicine every 12 hours for 48 hours including a combination of honey and ginger extract as gavage, in addition to the classical treatments for diabetes insipidus,  (10 ml of honey and 500 mg of ginger extract dissolved in 20 ml of distilled water). Conventional treatments for diabetes insipidus include replacing the deficit of fluids with intravenous or oral solutions with minimal sodium (half saline, dextrose 5% or water) with a daily volume of approximately 4 ml per kilogram of body weight and reducing the volume of urine through the administration of Desmopressin (synthetic analogue of vasopressin) nasal spray 1-2 puff (10-40 microgram) every 12 hours and the treatment of primary brain disease. Intervention 3: Control group: a group of patients who only received classic treatments for diabetes insipidus, including replacement of body fluids through intravenous (half-saline fluid) and oral root at the rate of 4 ml per kilogram of body weight in 24 hours and desmopressin nasal spray (a synthetic analogue of vasopressin) under the brand of Minirin), 1 to 2 puffs (10 to 40 mg) every 12 hours. As a placebo, the patient receives a syringe containing 30 cc of water every 12 hours for 48 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to the fact that sampling of patients has not been done yet, we have not made a decision to publish the data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen Savaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farvardin Street, Golestan</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15794 - 61357</zip>
        <telephone>+98 61 3311 0000</telephone>
        <email>drsavaie@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohsen Savaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Esfand Street, Golestan</address>
        <city>ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15794 - 61357</zip>
        <telephone>+98 61 3311 0000</telephone>
        <email>drsavaie@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Hospitalization in the intensive care unit
Having diagnostic criteria for diabetes insipidus
Signing the informed consent form by the patient's family
Establishment of enteral nutrition
Not having drug interactions with the drugs received by the patient based on the opinion of traditional medicine pharmacist colleagues</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Discontinuation of enteral feeding for any reason
Death of the patient due to various causes
Patient discharge
Declaration of non-consent by the patient's family to continue the plan
The occurrence of drug interactions with the drugs received by the patient based on the opinion of traditional medicine pharmacist colleagues</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E23.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes insipidus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: a group of patients who, receive traditional medicine including honey and frankincense extract as gavage every 12 hours for 48 hours in addition to classical treatments for diabetes insipidus,  (10 ml of honey and 500 mg of frankincense extract dissolved in 20 ml of distilled water). Conventional treatments for diabetes insipidus include replacing the deficit of fluids with intravenous or oral solutions with minimal sodium (half saline, dextrose 5% or water) with a daily volume of approximately 4 ml per kilogram of body weight and reducing the volume of urine through the administration of Desmopressin (synthetic analogue of vasopressin) nasal spray 1-2 puff (10-40 microgram) every 12 hours and the treatment of primary brain disease.</i_keyword>
      <i_keyword>Intervention group 2 : a group of patients who, receive traditional medicine every 12 hours for 48 hours including a combination of honey and ginger extract as gavage, in addition to the classical treatments for diabetes insipidus,  (10 ml of honey and 500 mg of ginger extract dissolved in 20 ml of distilled water). Conventional treatments for diabetes insipidus include replacing the deficit of fluids with intravenous or oral solutions with minimal sodium (half saline, dextrose 5% or water) with a daily volume of approximately 4 ml per kilogram of body weight and reducing the volume of urine through the administration of Desmopressin (synthetic analogue of vasopressin) nasal spray 1-2 puff (10-40 microgram) every 12 hours and the treatment of primary brain disease.</i_keyword>
      <i_keyword>Control group: a group of patients who only received classic treatments for diabetes insipidus, including replacement of body fluids through intravenous (half-saline fluid) and oral root at the rate of 4 ml per kilogram of body weight in 24 hours and desmopressin nasal spray (a synthetic analogue of vasopressin) under the brand of Minirin), 1 to 2 puffs (10 to 40 mg) every 12 hours. As a placebo, the patient receives a syringe containing 30 cc of water every 12 hours for 48 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient's urine volume during 24-hour. Timepoint: 24-hour urine volume measurement at the beginning of the study (before the start of the intervention) and 24 and 48 and 72 hours after the administration of placebo, honey-frankincense or honey-ginger combination. Method of measurement: 24-hour urine volume measurement by graduated urine bags connected to the patient's Foley catheter daily (every 24 hours).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Serum sodium level. Timepoint: Serum sodium level measurement at the beginning of the study (before the start of the intervention) and 24 and 48 and 72 hours after the administration of placebo, honey-frankincense or honey-ginger combination. Method of measurement: Laboratory measurement on blood sample by biochemistry autoanalyzer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-18</approval_date>
        <contact_name>Ethics Committee in Golestan Hospital Research</contact_name>
        <contact_address>Ahvaz, Golestan, Golestan Hospital ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
